{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:13:04Z","timestamp":1789693984756,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Basic and Applied Basic Research Program of Guangzhou","award":["202201011741"],"award-info":[{"award-number":["202201011741"]}]},{"name":"Basic and Applied Basic Research Program of Guangzhou","award":["202201011741"],"award-info":[{"award-number":["202201011741"]}]},{"name":"Guangzhou Science and Technology Project","award":["2023A03J0609"],"award-info":[{"award-number":["2023A03J0609"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"DOI":"10.1007\/s10143-024-02957-1","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T04:02:48Z","timestamp":1728446568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinicopathological, immunohistochemical and therapeutic approaches on survival in patients with epithelioid glioblastoma: Institutional experience in the management of 58 patients"],"prefix":"10.1007","volume":"47","author":[{"given":"Meng-nan","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-qun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang-fen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-dan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-yu","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-jun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-yao","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-bo","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-zheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"issue":"23","key":"2957_CR1","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A et al (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. Jama 318(23):2306\u201316. https:\/\/doi.org\/10.1001\/jama.2017.18718","journal-title":"Jama"},{"key":"2957_CR2","unstructured":"WHO Classification of Tumours Editorial Board (2021) Central nervous system tumours. Lyon (France): International Agency for Research on Cancer. (WHO classification of tumours series, 5th ed.; vol. 6). https:\/\/publications.iarc.fr\/601"},{"issue":"1","key":"2957_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/neup.12318","volume":"37","author":"N Matsumura","year":"2017","unstructured":"Matsumura N, Nakajima N, Yamazaki T et al (2017) Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma. Neuropathology 37(1):58\u201363. https:\/\/doi.org\/10.1111\/neup.12318","journal-title":"Neuropathology"},{"key":"2957_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/B978-0-12-802997-8.00005-0","volume":"134","author":"A Perry","year":"2016","unstructured":"Perry A, Wesseling P (2016) Histologic classification of gliomas. Handbook Clin Neurol 134:71\u201395. https:\/\/doi.org\/10.1016\/B978-0-12-802997-8.00005-0","journal-title":"Handbook Clin Neurol"},{"key":"2957_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.wneu.2019.08.007","volume":"131","author":"VM Lu","year":"2019","unstructured":"Lu VM, George ND, Brown DA et al (2019) Confirming Diagnosis and Effective Treatment for Rare Epithelioid Glioblastoma Variant: An Integrated Survival Analysis of the Literature. World Neurosurg 131:243\u201351.e2. https:\/\/doi.org\/10.1016\/j.wneu.2019.08.007","journal-title":"World Neurosurg"},{"issue":"Suppl 2","key":"2957_CR6","doi-asserted-by":"publisher","first-page":"e000520","DOI":"10.1136\/esmoopen-2019-000520","volume":"4","author":"M Weller","year":"2019","unstructured":"Weller M, Le Rhun E, Preusser M et al (2019) How we treat glioblastoma. ESMO Open 4(Suppl 2):e000520. https:\/\/doi.org\/10.1136\/esmoopen-2019-000520","journal-title":"ESMO Open"},{"issue":"5","key":"2957_CR7","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/bpa.12566","volume":"28","author":"A Korshunov","year":"2018","unstructured":"Korshunov A, Chavez L, Sharma T et al (2018) Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. Brain Pathol 28(5):656\u201362. https:\/\/doi.org\/10.1111\/bpa.12566","journal-title":"Brain Pathol"},{"issue":"6","key":"2957_CR8","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803\u201320. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"2957_CR9","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.2147\/OTT.S249317","volume":"13","author":"Y Zeng","year":"2020","unstructured":"Zeng Y, Zhu X, Wang Y et al (2020) Clinicopathological, immunohistochemical and molecular genetic study on epithelioid glioblastoma: a series of fifteen cases with literature review. OncoTargets Ther 13:3943\u201352. https:\/\/doi.org\/10.2147\/OTT.S249317","journal-title":"OncoTargets Ther"},{"issue":"2","key":"2957_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/bpa.12295","volume":"26","author":"S Alexandrescu","year":"2016","unstructured":"Alexandrescu S, Korshunov A, Lai SH et al (2016) Epithelioid glioblastomas and anaplastic epithelioid pleomorphic Xanthoastrocytomas-Same entity or first cousins? Brain Pathol 26(2):215\u201323. https:\/\/doi.org\/10.1111\/bpa.12295","journal-title":"Brain Pathol"},{"issue":"5","key":"2957_CR11","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/bpa.12572","volume":"28","author":"N Nakajima","year":"2018","unstructured":"Nakajima N, Nobusawa S, Nakata S et al (2018) BRAF V600E, TERT promoter mutations and CDKN2A\/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity. Brain Pathol 28(5):663\u201373. https:\/\/doi.org\/10.1111\/bpa.12572","journal-title":"Brain Pathol"},{"key":"2957_CR12","doi-asserted-by":"publisher","first-page":"151679","DOI":"10.1016\/j.anndiagpath.2020.151679","volume":"50","author":"D Chatterjee","year":"2021","unstructured":"Chatterjee D, Radotra BD, Aggarwal D et al (2021) Analysis of 24 cases of epithelioid glioblastoma: Experience from a tertiary centre of North India. Ann Diagn Pathol 50:151679. https:\/\/doi.org\/10.1016\/j.anndiagpath.2020.151679","journal-title":"Ann Diagn Pathol"},{"issue":"7","key":"2957_CR13","first-page":"1529","volume":"13","author":"S Wang","year":"2020","unstructured":"Wang S, He Q, Zhang Q et al (2020) Clinicopathologic features and prognosis of epithelioid glioblastoma. Int J Clin Exp Pathol 13(7):1529\u201339","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"2957_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/neuonc\/noac177","volume":"25","author":"R Drexler","year":"2023","unstructured":"Drexler R, Sch\u00fcller U, Eckhardt A et al (2023) DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients. Neuro-oncology 25(2):315\u201325. https:\/\/doi.org\/10.1093\/neuonc\/noac177","journal-title":"Neuro-oncology"},{"issue":"6","key":"2957_CR15","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1007\/s10143-021-01492-7","volume":"44","author":"K Sun","year":"2021","unstructured":"Sun K, Zhou X, Li T et al (2021) Clinicopathological characteristics and treatment outcomes of epithelioid glioblastoma. Neurosurg Rev 44(6):3335\u201348. https:\/\/doi.org\/10.1007\/s10143-021-01492-7","journal-title":"Neurosurg Rev"},{"issue":"12","key":"2957_CR16","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1093\/neuonc\/noaa107","volume":"22","author":"Carmen Balana","year":"2020","unstructured":"Balana Carmen, Vaz Maria Angeles, Sep\u00falveda Juan Manuel et al (2020) A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14\u201301). Neuro-oncology 22(12):1851\u201361. https:\/\/doi.org\/10.1093\/neuonc\/noaa107","journal-title":"Neuro-oncology"},{"issue":"4","key":"2957_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/neuonc\/nov326","volume":"18","author":"B Suchorska","year":"2016","unstructured":"Suchorska B, Weller M, Tabatabai G et al (2016) Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro-oncology 18(4):549\u201356. https:\/\/doi.org\/10.1093\/neuonc\/nov326","journal-title":"Neuro-oncology"},{"key":"2957_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.radonc.2021.12.019","volume":"167","author":"P Navarria","year":"2022","unstructured":"Navarria P, Pessina F, Clerici E et al (2022) Re-irradiation for recurrent high grade glioma (HGG) patients: Results of a single arm prospective phase 2 study. Radiother Oncol 167:89\u201396. https:\/\/doi.org\/10.1016\/j.radonc.2021.12.019","journal-title":"Radiother Oncol"},{"issue":"1","key":"2957_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13014-021-01767-9","volume":"16","author":"G Minniti","year":"2021","unstructured":"Minniti G, Niyazi M, Alongi F et al (2021) Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol 16(1):36. https:\/\/doi.org\/10.1186\/s13014-021-01767-9","journal-title":"Radiat Oncol"},{"issue":"3","key":"2957_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11060-017-2383-2","volume":"132","author":"M Azoulay","year":"2017","unstructured":"Azoulay M, Santos F, Shenouda G et al (2017) Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution. J Neuro-Oncol 132(3):419\u201326. https:\/\/doi.org\/10.1007\/s11060-017-2383-2","journal-title":"J Neuro-Oncol"},{"issue":"5","key":"2957_CR21","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/nop\/npz017","volume":"6","author":"CH Chapman","year":"2019","unstructured":"Chapman CH, Hara JH, Molinaro AM et al (2019) Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival. Neuro-oncol Pract 6(5):364\u201374. https:\/\/doi.org\/10.1093\/nop\/npz017","journal-title":"Neuro-oncol Pract"},{"key":"2957_CR22","doi-asserted-by":"publisher","first-page":"1067252","DOI":"10.3389\/fonc.2022.1067252","volume":"12","author":"V Di Nunno","year":"2022","unstructured":"Di Nunno V, Gatto L, Tosoni A et al (2022) Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution. Front Oncol 12:1067252. https:\/\/doi.org\/10.3389\/fonc.2022.1067252","journal-title":"Front Oncol"},{"issue":"5","key":"2957_CR23","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/PAS.0b013e31827f9c5e","volume":"37","author":"BK Kleinschmidt-Demasters","year":"2013","unstructured":"Kleinschmidt-Demasters BK, Aisner DL, Birks DK et al (2013) Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 37(5):685\u201398. https:\/\/doi.org\/10.1097\/PAS.0b013e31827f9c5e","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2957_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13000-016-0506-2","volume":"11","author":"F Behling","year":"2016","unstructured":"Behling F, Barrantes-Freer A, Skardelly M et al (2016) Frequency of BRAF V600E mutations in 969 central nervous system neoplasms. Diagn Pathol 11(1):55. https:\/\/doi.org\/10.1186\/s13000-016-0506-2","journal-title":"Diagn Pathol"},{"issue":"5","key":"2957_CR25","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00401-015-1405-4","volume":"129","author":"A Korshunov","year":"2015","unstructured":"Korshunov A, Ryzhova M, Hovestadt V et al (2015) Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 129(5):669\u201378. https:\/\/doi.org\/10.1007\/s00401-015-1405-4","journal-title":"Acta Neuropathol"},{"issue":"4","key":"2957_CR26","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.18632\/oncotarget.5456","volume":"7","author":"RQ Zhang","year":"2016","unstructured":"Zhang RQ, Shi Z, Chen H et al (2016) Biomarker-based prognostic stratification of young adult glioblastoma. Oncotarget. 7(4):5030\u201341. https:\/\/doi.org\/10.18632\/oncotarget.5456","journal-title":"Oncotarget."},{"issue":"7315","key":"2957_CR27","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nature09454","volume":"467","author":"G Bollag","year":"2010","unstructured":"Bollag G, Hirth P, Tsai J et al (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467(7315):596\u20139. https:\/\/doi.org\/10.1038\/nature09454","journal-title":"Nature"},{"issue":"26","key":"2957_CR28","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med 364(26):2507\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1103782","journal-title":"New Engl J Med"},{"issue":"4","key":"2957_CR29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2217\/cns-2017-0006","volume":"6","author":"NF Brown","year":"2017","unstructured":"Brown NF, Carter T, Kitchen N et al (2017) Dabrafenib and trametinib in BRAFV600E mutated glioma. CNS Oncol 6(4):291\u20136. https:\/\/doi.org\/10.2217\/cns-2017-0006","journal-title":"CNS Oncol"},{"key":"2957_CR30","doi-asserted-by":"publisher","unstructured":"Ceccon G, Werner J M, Dunkl V, et al (2018) Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation. Int J Mol Sci 19(4). https:\/\/doi.org\/10.3390\/ijms19041090","DOI":"10.3390\/ijms19041090"},{"issue":"1","key":"2957_CR31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s40478-019-0774-7","volume":"7","author":"Y Kanemaru","year":"2019","unstructured":"Kanemaru Y, Natsumeda M, Okada M et al (2019) Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy. Acta Neuropathol Commun 7(1):119. https:\/\/doi.org\/10.1186\/s40478-019-0774-7","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"2957_CR32","doi-asserted-by":"publisher","first-page":"Cns48","DOI":"10.2217\/cns-2019-0018","volume":"8","author":"M Smith-Cohn","year":"2019","unstructured":"Smith-Cohn M, Davidson C, Colman H et al (2019) Challenges of targeting BRAF V600E mutations in adult primary brain tumor patients: a report of two cases. CNS Oncol 8(4):Cns48. https:\/\/doi.org\/10.2217\/cns-2019-0018","journal-title":"CNS Oncol"},{"issue":"6","key":"2957_CR33","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/bpa.12887","volume":"30","author":"N Nakagomi","year":"2020","unstructured":"Nakagomi N, Sakamoto D, Hirose T et al (2020) Epithelioid glioblastoma with microglia features: potential for novel therapy. Brain Pathol 30(6):1119\u201333. https:\/\/doi.org\/10.1111\/bpa.12887","journal-title":"Brain Pathol"},{"issue":"22","key":"2957_CR34","doi-asserted-by":"publisher","first-page":"6197","DOI":"10.1158\/1078-0432.CCR-21-2660","volume":"27","author":"KC Schreck","year":"2021","unstructured":"Schreck KC, Morin A, Zhao G et al (2021) Deconvoluting mechanisms of acquired resistance to RAF inhibitors in BRAF(V600E)-Mutant human glioma. Clin Cancer Res 27(22):6197\u2013208. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2660","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2957_CR35","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1002\/jcp.25952","volume":"233","author":"A Bahrami","year":"2018","unstructured":"Bahrami A, Hesari A, Khazaei M et al (2018) The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer. J Cell Physiol 233(3):2162\u20139. https:\/\/doi.org\/10.1002\/jcp.25952","journal-title":"J Cell Physiol"},{"key":"2957_CR36","doi-asserted-by":"publisher","unstructured":"Dratkiewicz E, Simiczyjew A, Pietraszek-Gremplewicz K, et al (2019) Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment. Int J Mol Sci 21(1). https:\/\/doi.org\/10.3390\/ijms21010113","DOI":"10.3390\/ijms21010113"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-024-02957-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-024-02957-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-024-02957-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T05:41:10Z","timestamp":1741066870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-024-02957-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2957"],"URL":"https:\/\/doi.org\/10.1007\/s10143-024-02957-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4674275\/v1","asserted-by":"object"}]},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"assertion":[{"value":"2 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Ethics Committee of Guangdong Sanjiu Brain Hospital (No.202101017), and there was informed consent exemption for all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"763"}}